Monotherapy with histamine dihydrochloride suppresses in vivo growth of a rat sarcoma in liver and subcutis.
The effect of parenterally-administered histamine dihydrochloride (histamine), the role of the histamine H2-receptor and the importance of histamine administration routes on the in vivo growth of a rat Leydig cell sarcoma (LTW) were explored.


METHODS
Wistar/Furth rats with LTW tumours transplanted into subcutaneous and liver tissue received treatment by daily subcutaneous injections or by an osmotic pump for 10 days.


RESULTS
Subcutaneous injections of histamine (0.5 mg/kg) reduced the liver tumour weight by 46+/-8% (p=0.0002) and subcutaneous tumour weight by 41+/-12% (p=0.026) versus animals receiving subcutaneous saline injections. Histamine continuously administered by osmotic pumps at doses of 0.5, 2 and 20 mg/kg/24 hour, did not reduce tumour growth. Ranitidine (50 mg/kg s.c.), inhibited the anti-tumour effect observed by subcutaneous histamine injections. In conclusion, H2-receptor-mediated tumour growth inhibition was accomplished by bolus injections of histamine.
Rizell
Magnus
M
Department of Surgery, Sahlgrenska University Hospital, Gĵteborg, Sweden. magnus.rizell@surgery.gu.se
Hellstrand
Kristoffer
K
Lindnér
Per
P
Naredi
Peter
P
D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D005260:Female; D006632:Histamine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007263:Infusions, Parenteral; D007279:Injections, Subcutaneous; D007985:Leydig Cells / Q000187:drug effects / Q000473:pathology; D008113:Liver Neoplasms / Q000473:pathology* / Q000517:prevention & control; D008297:Male; D051381:Rats; D011920:Rats, Inbred WF; D012513:Sarcoma, Experimental / Q000473:pathology* / Q000517:prevention & control; D012878:Skin Neoplasms / Q000473:pathology* / Q000517:prevention & control
D016588:Anticarcinogenic Agents; D006632:Histamine